The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) is characterized by deposition of amyloid-β (Aβ) plaques and neurofibrillary tangles in the brain, accompanied by synaptic dysfunction and neurodegeneration. Antibody-based immunotherapy against Aβ to trigger its clearance or mitigate its neurotoxicity has so far been unsuccessful. Here we report the generation of aducanumab, a human monoclonal antibody that selectively targets aggregated Aβ. In a transgenic mouse model of AD, aducanumab is shown to enter the brain, bind parenchymal Aβ, and reduce soluble and insoluble Aβ in a dose-dependent manner. In patients with prodromal or mild AD, one year of monthly intravenous infusions of aducanumab reduces brain Aβ in a dose- and time-dependent manner. This is accompanied by a slowing of clinical decline measured by Clinical Dementia Rating-Sum of Boxes and Mini Mental State Examination scores. The main safety and tolerability findings are amyloid-related imaging abnormalities. These results justify further development of aducanumab for the treatment of AD. Should the slowing of clinical decline be confirmed in ongoing phase 3 clinical trials, it would provide compelling support for the amyloid hypothesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Aducanumab (1) binds to 3-7 amino acids of Aβ, targeting soluble oligomers and insoluble fibrils.418,419”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [418]
In the citing paper
“Aducanumab has been tested in a phase II study, demonstrating its biological effect in terms of Aβ removal via PET with amyloid tracer [56].”
From Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies (2023) · cites this paper as [56]
In the citing paper
“Additionally, amyloid was cleared from the six cortical regions of interest, namely the frontal, parietal, lateral temporal, sensorimotor, anterior, and posterior cingulate areas [43].”
From Clinical trials of new drugs for Alzheimer disease (2020) · cites this paper as [43]
In the citing paper
“Studies have shown that amyloid deposition was reduced in all treatment groups at 26 weeks and further reduced by the end of the first year.”
From Clinical trials of new drugs for Alzheimer disease (2020) · cites this paper as [43]
In the citing paper
“Anti-Aβ immunotherapies have shown reductions in amyloid PET and several amyloid reducing therapies for AD use amyloid PET (or CSF) as a key endpoint [172, 173].”
From The use of neuroimaging techniques in the early and differential diagnosis of dementia (2023) · cites this paper as [173]
20 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Villemagne, V. L., Burnham, S., Bourgeat, P., Brown, B., Ellis, K. A., Salvado, O., Szoeke, C., Macaulay, S. L., Martins, R., Maruff, P., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70044-9 · Cited by 2,279
Bard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012
The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes
Benilova, I., Karran, E., & De Strooper, B. (2012) · Nature Neuroscience · doi:10.1038/nn.3028 · Cited by 1,962
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Self-citation
Cited by
Items 401–500 of 1,043
Ono, K., & Tsuji, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030952 · Cited by 92
“Since aducanumab may also bind aggregates such as oligomers of Aβ [65], these results may be important for interpreting data from the phase 3 clinical trial of BAN2401.”
ResultGenomics of Alzheimer’s disease implicates the innate and adaptive immune systems
Li, Y., Laws, S. M., Miles, L. A., Wiley, J. S., Huang, X., Masters, C. L., & Gu, B. J. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03986-5 · Cited by 111
Doré, V., Bullich, S., Rowe, C. C., Bourgeat, P., Konate, S., Sabri, O., Stephens, A. W., Barthel, H., Fripp, J., Masters, C. L., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.02.005 · Cited by 93
Cerebral amyloid angiopathy in Down syndrome and sporadic and autosomal‐dominant Alzheimer's disease
Carmona‐Iragui, M., Balasa, M., Benejam, B., Alcolea, D., Fernández, S., Videla, L., Sala, I., Sánchez‐Saudinós, M. B., Morenas‐Rodriguez, E., Ribosa‐Nogué, R., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.03.007 · Cited by 89
“On the other hand, the APOE ε4 genotype is also commonly used to stratify participants given its influence on ARIAs [37]; however, this strategy might not be as important in ADAD or DS. Finally, our data also suggest that the CSF Ab40 levels will not be a useful biomarker in these trials.”
InfluentialDown syndrome and Alzheimer's disease: common molecular traits beyond the amyloid precursor protein
Gómez, W., Morales, R., Maracaja‐Coutinho, V., Parra, V., & Nassif, M. (2020) · Aging · doi:10.18632/aging.102677 · Cited by 103
“This antibody targets aggregated forms of Aβ, in the hope of reducing its accumulation [138].”
BackgroundPlasma p‐tau231, p‐tau181, PET Biomarkers, and Cognitive Change in Older Adults
Meyer, P., Ashton, N. J., Karikari, T. K., Strikwerda‐Brown, C., Köbe, T., Gonneaud, J., Pichet Binette, A., Ozlen, H., Yakoub, Y., Simrén, J., et al. (2022) · Annals of Neurology · doi:10.1002/ana.26308 · Cited by 91
“Unfortunately, even Aβ-targeting interventions that achieve robust removal of plaques have failed to slow cognitive decline.(50) As is true in many chronic diseases, early treatment may improve chances of success,(4) thus indicating the potential value of tools for detection and measurement of AD pathogenesis.”
BackgroundGroot, C., Cicognola, C., Bali, D., Triana-Baltzer, G., Dage, J. L., Pontecorvo, M. J., Kolb, H. C., Ossenkoppele, R., Janelidze, S., & Hansson, O. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-01005-8 · Cited by 99
Neuroinflammation: Mechanisms, Dual Roles, and Therapeutic Strategies in Neurological Disorders
García‐Domínguez, M. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47060417 · Cited by 105
BACE inhibitors in clinical development for the treatment of Alzheimer’s disease
Panza, F., Lozupone, M., Solfrizzi, V., Sardone, R., Piccininni, C., Dibello, V., Stallone, R., Giannelli, G., Bellomo, A., Greco, A., et al. (2018) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2018.1531706 · Cited by 92
Kellar, D., Lockhart, S. N., Aisen, P., Raman, R., Rissman, R. A., Brewer, J., & Craft, S. (2021) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2021.14 · Cited by 91
“Clinical trials have attempted to reduce accumulation of these proteins in the brain and prevent further cognitive decline; however, although some amyloid antibody trials have successfully reduced plaque load, none have been successful to date in halting the progression of AD symptoms (2, 3).”
BackgroundNaturally Occurring Antioxidant Therapy in Alzheimer’s Disease
Collins, A. E., Saleh, T. M., & Kalisch, B. E. (2022) · Antioxidants · doi:10.3390/antiox11020213 · Cited by 102
Cell models for Alzheimer’s and Parkinson’s disease: At the interface of biology and drug discovery
Cetin, S., Knez, D., Gobec, S., Kos, J., & Pišlar, A. H. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112924 · Cited by 107
Metabolic Dysfunction in Alzheimer’s Disease: From Basic Neurobiology to Clinical Approaches
Clarke, J. R., Ribeiro, F. C., Frozza, R. L., De Felice, F. G., & Lourenco, M. V. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179911 · Cited by 87
Yang, T., Dang, Y., Ostaszewski, B., Mengel, D., Steffen, V., Rabe, C., Bittner, T., Walsh, D. M., & Selkoe, D. J. (2019) · Annals of Neurology · doi:10.1002/ana.25513 · Cited by 91
Signs and Artifacts in Amyloid PET
Lundeen, T. F., Seibyl, J. P., Covington, M. F., Eshghi, N., & Kuo, P. H. (2018) · RadioGraphics · doi:10.1148/rg.2018180160 · Cited by 90
Anti-inflammatory clearance of amyloid-β by a chimeric Gas6 fusion protein
Jung, H., Lee, S. Y., Lim, S., Choi, H. R., Choi, Y., Kim, M., Kim, S., Lee, Y., Han, K. H., Chung, W., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01926-9 · Cited by 95
Kell, D. B., & Pretorius, E. (2016) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2016.08.006 · Cited by 96
Targeting tau: clinical trials and novel therapeutic approaches
VandeVrede, L., Boxer, A. L., & Polydoro, M. (2020) · Neuroscience Letters · doi:10.1016/j.neulet.2020.134919 · Cited by 90
Amyloid-related Imaging Abnormalities in Alzheimer Disease Treated with Anti–Amyloid-β Therapy
Agarwal, A., Gupta, V., Brahmbhatt, P., Desai, A., Vibhute, P., Joseph-Mathurin, N., & Bathla, G. (2023) · RadioGraphics · doi:10.1148/rg.230009 · Cited by 90
Meningeal Lymphatics in Central Nervous System Diseases
Salvador, A. F., Abduljawad, N., & Kipnis, J. (2024) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-113023-103045 · Cited by 99
“Intact meningeal lymphatics are also critical for the efficiency of passive immunotherapy (Sevigny et al. 2016) against A β (Da Mesquita et al. 2021b).”
The informed road map to prevention of Alzheimer Disease: a call to arms
McDade, E., Llibre-Guerra, J. J., Holtzman, D. M., Morris, J. C., & Bateman, R. J. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00467-y · Cited by 89
Liu, M., Bai, X., Yu, S., Zhao, W., Qiao, J., Liu, Y., Zhao, D., Wang, J., & Wang, S. (2019) · Molecules · doi:10.3390/molecules24152687 · Cited by 90
Antibodies inhibit transmission and aggregation of C9orf72 poly‐ GA dipeptide repeat proteins
Zhou, Q., Lehmer, C., Michaelsen, M., Mori, K., Alterauge, D., Baumjohann, D., Schludi, M. H., Greiling, J., Farny, D., Flatley, A., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201607054 · Cited by 89
Friend, Foe or Both? Immune Activity in Alzheimer’s Disease
Frost, G. R., Jonas, L. A., & Li, Y.-M. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00337 · Cited by 87
“In August 2016, very promising phase I results were published showing that Aducanumab decreased soluble and fibrillar forms of Aβ and slowed down cognitive decline 54 weeks after treatment in a dose-dependent manner (Sevigny et al., 2016).”
BackgroundLoeffler, D. A. (2023) · Journal of Alzheimer's Disease Reports · doi:10.3233/adr-230025 · Cited by 79
Uhlmann, R. E., Rother, C., Rasmussen, J., Schelle, J., Bergmann, C., Ullrich Gavilanes, E. M., Fritschi, S. K., Buehler, A., Baumann, F., Skodras, A., et al. (2020) · Nature Neuroscience · doi:10.1038/s41593-020-00737-w · Cited by 87
Self-citationVillain, N., Planche, V., & Levy, R. (2022) · Revue Neurologique · doi:10.1016/j.neurol.2022.06.012 · Cited by 87
Critical Appraisal of Amyloid Lowering Agents in AD
Decourt, B., Boumelhem, F., Pope, E. D., Shi, J., Mari, Z., & Sabbagh, M. N. (2021) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-021-01125-y · Cited by 85
Rai, H., Gupta, S., Kumar, S., Yang, J., Singh, S. K., Ran, C., & Modi, G. P. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01619 · Cited by 90
Microfluidic neural probes: in vivo tools for advancing neuroscience
Sim, J. Y., Haney, M. P., Park, S. I., McCall, J. G., & Jeong, J. (2017) · Lab on a Chip · doi:10.1039/c7lc00103g · Cited by 94
Pitt, J., Wilcox, K. C., Tortelli, V., Diniz, L. P., Oliveira, M. S., Dobbins, C., Yu, X.-W., Nandamuri, S., Gomes, F. C. A., DiNunno, N., et al. (2017) · Molecular Biology of the Cell · doi:10.1091/mbc.e17-06-0416 · Cited by 84
“, 2009), such an accelerating feedback loop would likely require several levels of therapeutic intervention, optimally combining anti-AβO therapy using antibodies capable of recognizing oligomers, such as Aducanumab (Sevigny et al., 2016), together with CNS-targeted insulin therapy (Craft et al.”
BackgroundInfluentialIsrael, L. L., Braubach, O., Galstyan, A., Chiechi, A., Shatalova, E. S., Grodzinski, Z. B., Ding, H., Black, K. L., Ljubimova, J. Y., & Holler, E. (2019) · ACS Nano · doi:10.1021/acsnano.8b06437 · Cited by 99
Bassoon proteinopathy drives neurodegeneration in multiple sclerosis
Schattling, B., Engler, J. B., Volkmann, C., Rothammer, N., Woo, M. S., Petersen, M., Winkler, I., Kaufmann, M., Rosenkranz, S. C., Fejtova, A., et al. (2019) · Nature Neuroscience · doi:10.1038/s41593-019-0385-4 · Cited by 86
Stabilization and structural analysis of a membrane-associated hIAPP aggregation intermediate
Camargo, D. C. R., Korshavn, K. J., Jussupow, A., Raltchev, K., Goričanec, D., Fleisch, M., Sarkar, R., Xue, K., Aichler, M., Mettenleiter, G., et al. (2017) · eLife · doi:10.7554/elife.31226 · Cited by 89
“Sequence- and conformation-specific antibod- ies have been developed as tools for basic research and potential therapeutics (Kayed et al., 2010; Lee et al., 2016; Sevigny et al., 2016).”
BackgroundWang, L., & Mao, X. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052360 · Cited by 97
Callens, M., Kraskovskaya, N., Derevtsova, K. Z., Annaert, W. G., Bultynck, G., Борисович, Б. И., & Vervliet, T. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2021.118997 · Cited by 93
Edavettal, S. C., Cejudo–Martín, P., Dasgupta, B., Yang, D., Buschman, M. D., Domingo, D. L., Kolen, K. V., Jaiprasart, P., Gordon, R. E., Schutsky, K., et al. (2022) · Med · doi:10.1016/j.medj.2022.09.007 · Cited by 94
Cummings, J. L. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00570 · Cited by 94
“A Phase 1B trial of aducanumab demonstrated marked reduction of A β plaque after 12 months of exposure in the participants receiving monthly infusions at a dose of 10 mg/kg [28].”
Farid, K., Charidimou, A., & Baron, J. (2017) · NeuroImage Clinical · doi:10.1016/j.nicl.2017.05.002 · Cited by 95
“This in turn opens new avenues for proper application of future therapies, and for directly monitoring the latter's e ff ects (Sevigny et al., 2016).”
BackgroundMaier, M., Welt, T., Wirth, F., Montrasio, F., Preisig, D. F., McAfoose, J., Vieira, F. G., Kulic, L., Späni, C. B., Stehle, T., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aah3924 · Cited by 86
Self-citationMicrovascular Alterations in Alzheimer's Disease
Steinman, J., Sun, H.-S., & Feng, Z.-P. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.618986 · Cited by 81
“Aducanumab, a human monoclonal antibody directed against Aβ, reduced soluble and insoluble parenchymal Aβ in Tg2576 AD mice, while reducing Aβ in humans and slowing clinical decline (Sevigny et al., 2016).”
BackgroundWitika, B. A., Poka, M., Demana, P. H., Matafwali, S. K., Melamane, S., Khamanga, S. M., & Makoni, P. A. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14040836 · Cited by 93
Exploring cerebral amyloid angiopathy: Insights into pathogenesis, diagnosis, and treatment
Cozza, M., Amadori, L., & Boccardi, V. (2023) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2023.120866 · Cited by 94
Syvänen, S., Hultqvist, G., Gustavsson, T., Gumucio, A., Laudon, H., Söderberg, L., Ingelsson, M., Lannfelt, L., & Sehlin, D. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0377-8 · Cited by 91
“In this respect, mAb158/BAN2401 may differ from aducanumab, which is reported to bind fibrillar Aβ with high affinity [8].”
BackgroundInfluentialIron Dysregulation in Mitochondrial Dysfunction and Alzheimer’s Disease
Onukwufor, J. O., Dirksen, R. T., & Wojtovich, A. P. (2022) · Antioxidants · doi:10.3390/antiox11040692 · Cited by 93
Multiscale optical and optoacoustic imaging of amyloid-β deposits in mice
Ni, R., Chen, Z., Deán‐Ben, X. L., Voigt, F. F., Kirschenbaum, D. S., Shi, G., Villois, A., Zhou, Q., Crimi, A., Arosio, P., et al. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00906-1 · Cited by 91
Self-citationRabinovici, G. D., Knopman, D. S., Arbizu, J., Benzinger, T. L. S., Donohoe, K. J., Hansson, O., Herscovitch, P., Kuo, P. H., Lingler, J. H., Minoshima, S., et al. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.268756 · Cited by 90
Self-citationTwo decades of new drug discovery and development for Alzheimer's disease
Liu, Z., Zhang, A., Sun, H., Han, Y., Kong, L., & Wang, X. (2017) · RSC Advances · doi:10.1039/c6ra26737h · Cited by 83
Addendum: The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2017) · Nature · doi:10.1038/nature22809 · Cited by 83
Self-citationMeng, Y., Goubran, M., Rabin, J. S., McSweeney, M., Ottoy, J., Pople, C. B., Huang, Y., Storace, A., Ozzoude, M., Bethune, A., et al. (2023) · Brain · doi:10.1093/brain/awac459 · Cited by 83
Shimada, H., Kitamura, S., Shinotoh, H., Endo, H., Niwa, F., Hirano, S., Kimura, Y., Zhang, M., Kuwabara, S., Suhara, T., et al. (2017) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2016.12.009 · Cited by 81
“diagnosis [3,4], predict disease progression [5], build a better understanding of the pathogenesis [6–9], and evaluate therapeutic efficacies in clinical trials [10,11].”
BackgroundRosenfeld, P. J., Berger, B. B., Reichel, E., Danis, R. P., Gress, A., Ye, L., Magee, M. H., Parham, L. R., & McLaughlin, M. (2018) · Ophthalmology Retina · doi:10.1016/j.oret.2018.03.001 · Cited by 83
A Rationally Designed Humanized Antibody Selective for Amyloid Beta Oligomers in Alzheimer’s Disease
Gibbs, E., Silverman, J. M., Zhao, B., Peng, X., Wang, J., Wellington, C. L., Mackenzie, I. R., Plotkin, S. S., Kaplan, J. M., & Cashman, N. R. (2019) · Scientific Reports · doi:10.1038/s41598-019-46306-5 · Cited by 82
Proteotoxicity and Neurodegenerative Diseases
Ruz, C., Alcantud, J. L., Montero, F. V., Durán, R., & Bandrés‐Ciga, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165646 · Cited by 89
“Preliminary results after treatment with aducanumab (monoclonal antibody that selectively reacts with Aβ aggregates) have showed a reduction of brain Aβ plaques together with a slowing of clinical decline in patients with prodromal or mild AD [197].”
Neurotoxic β-amyloid oligomers cause mitochondrial dysfunction—the trigger for PANoptosis in neurons
Meng, X., Song, Q., Liu, Z., Liu, X., Wang, Y., & Liu, J. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1400544 · Cited by 88
“…high-affinity drugs such as the FDA-approved drugs aducanumab and donanemab, which activate the immune system in patients and cause it to clear A β Os and amyloid plaques from the brain, require high doses to neutralize a small fraction of A β Os (Sevigny et al., 2016; Knopman et al., 2021).”
BackgroundAdult-Onset Epilepsy in Presymptomatic Alzheimer’s Disease: A Retrospective Study
DiFrancesco, J. C., Tremolizzo, L., Polonia, V., Giussani, G., Bianchi, E., Franchi, C., Nobili, A., Appollonio, I., Beghi, E., & Ferrarese, C. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-170392 · Cited by 81
Preclinical Alzheimer's disease: A systematic review of the cohorts underlying the concept
Epelbaum, S., Genthon, R., Cavedo, E., Habert, M. O., Lamari, F., Gagliardi, G., Lista, S., Teichmann, M., Bakardjian, H., Hampel, H., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.12.003 · Cited by 77
“possible efficacy of disease modifying drugs in the early clinical stage of AD [24,27].”
BackgroundMuraoka, S., Hirano, M., Isoyama, J., Nagayama, S., Tomonaga, T., & Adachi, J. (2022) · iScience · doi:10.1016/j.isci.2022.104012 · Cited by 89
“In 2021, the Food and Drug Administration (FDA) approved Aduhelm (aducanumab), which reduces soluble and insoluble amyloid beta in the brain, for the treatment of early Alzheimer disease (AD) (Sevigny et al., 2016).”
BackgroundEgan, M. F., Mukai, Y., Voss, T., Kost, J., Stone, J., Furtek, C., Mahoney, E., Cummings, J. L., Tariot, P. N., Aisen, P. S., et al. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0520-1 · Cited by 81
Caselli, R. J., Beach, T. G., Knopman, D. S., & Graff-Radford, N. R. (2017) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.02.011 · Cited by 81
Early diagnosis and treatment of Alzheimer’s disease by targeting toxic soluble Aβ oligomers
Habashi, M., Vutla, S., Tripathi, K. K., Senapati, S., Chauhan, P. S., Haviv‐Chesner, A., Richman, M., Mohand, S.-A., Dumulon‐Perreault, V., Mulamreddy, R., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2210766119 · Cited by 88
“Recently, two monoclonal antibodies targeting A β oligomers have shown encouraging therapeutic efficacy in phase III clinical studies, and the antibody Aducanumab has received US Food and Drug Administration (FDA) approval (16–18).”
Tau oligomers mediate α-synuclein toxicity and can be targeted by immunotherapy
Gerson, J. E., Farmer, K. M., Henson, N., Castillo-Carranza, D. L., Carretero Murillo, M., Sengupta, U., Barrett, A., & Kayed, R. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0245-9 · Cited by 77
“Passive immunotherapy is a promising mode of treatment, with a recent anti-amyloid oligomer antibody showing promising results [1].”
BackgroundJo, T., Nho, K., Bice, P., Saykin, A. J., & Initiative, F. T. A. D. N. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac022 · Cited by 80
Amyloid-Targeting Monoclonal Antibodies for Alzheimer Disease
Rabinovici, G. D., & La Joie, R. (2023) · JAMA · doi:10.1001/jama.2023.11703 · Cited by 80
Roseborough, A. D., Saad, L., Goodman, M., Cipriano, L. E., Hachinski, V. C., & Whitehead, S. N. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12642 · Cited by 80
Uekawa, K., Hattori, Y., Ahn, S. J., Seo, J., Casey, N., Anfray, A., Zhou, P., Luo, W., Anrather, J., Park, L., et al. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00660-1 · Cited by 80
“ARIA is observed with MRI in cortical areas in up to 47% of patients receiving Aβ immunotherapy at the highest dose [86, 87].”
TLR5 decoy receptor as a novel anti-amyloid therapeutic for Alzheimer’s disease
Chakrabarty, P., Li, A., Ladd, T. B., Strickland, M. R., Koller, E. J., Burgess, J. D., Funk, C. C., Cruz, P. E., Allen, M., Yaroshenko, M., et al. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20180484 · Cited by 78
Sabbagh, M. N., Hendrix, S., & Harrison, J. E. (2019) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.11.004 · Cited by 80
“[21] Sevigny J, Chiao P, Bussi ere T, Weinreb PH, Williams L, Maier M,”
BackgroundMethodStructure-Based Peptide Inhibitor Design of Amyloid-β Aggregation
Lu, J., Cao, Q., Wang, C., Zheng, J., Luo, F., Xie, J., Li, Y., Ma, X., He, L., Eisenberg, D., et al. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00054 · Cited by 78
Therapeutic Antibodies in Medicine
Sharma, P., Joshi, R. V., Pritchard, R., Xu, K., & Eicher, M. A. (2023) · Molecules · doi:10.3390/molecules28186438 · Cited by 90
“Neurologic Aducanumab Aduhelm Amyloid β Human IgG1 Alzheimer’s disease [254] 2021 MAA withdrawn”
BackgroundThe Role of Genetics in Advancing Precision Medicine for Alzheimer’s Disease—A Narrative Review
Freudenberg-Hua, Y., Li, W., & Davies, P. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00108 · Cited by 74
“Biogen’s immunotherapeutic drug Aducanumab reported positive Phase 1 results on removing brain Aβ plaques and clinical benefits (133).”
BackgroundCan exercise training teach us how to treat Alzheimer's disease?
Huuha, A. M., Norevik, C. S., Moreira, J. B. N., Kobro-Flatmoen, A., Scrimgeour, N., Kivipelto, M., Van Praag, H., Ziaei, M., Sando, S. B., Wisløff, U., et al. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101559 · Cited by 79
Esteve, P., Rueda‐Carrasco, J., Mateo, M. I., Martín‐Bermejo, M. J., Draffin, J. E., Pereyra, G., Sandonís, Á., Crespo, I., Moreno, I., Aso, E., et al. (2019) · Nature Neuroscience · doi:10.1038/s41593-019-0432-1 · Cited by 87
Rabin, J. S., Nichols, E., Joie, R. L., Casaletto, K. B., Palta, P., Dams-O’Connor, K., Kumar, R. G., George, K. M., Satizábal, C. L., Schneider, J. A., et al. (2022) · Brain · doi:10.1093/brain/awac178 · Cited by 85
Islet amyloid polypeptide: Another key molecule in Alzheimer’s pathogenesis?
Zhang, Y., & Song, W. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.03.001 · Cited by 83
Hernandez, A. M., Urbanke, H., Gillman, A. L., Lee, J., Ryazanov, S., Agbemenyah, H. Y., Benito, E., Jain, G., Kaurani, L., Grigorian, G., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201707825 · Cited by 82
“…of Ab peptides in the brain appears to be a key event in the pathogenesis of AD (Iversen et al, 1995; Tanzi, 2005; Jakob-Roetne & Jacobsen, 2009; Goate & Hardy, 2012), and targeting amyloid pathology still represents a promising therapeutic strategy (Haass & Selkoe, 2007; Sevigny et al, 2016).”
BackgroundUllah, R., Park, T. J., Huang, X., & Kim, M. O. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101451 · Cited by 78
“…(b) autoantibodies (e.g., promising results achieved with FDA approved-aducanumab; first human anti-Aβ-peptide autoantibody (DeMarshall et al., 2016; Sevigny et al., 2016); (c) blood RNA profiles, in particular, microRNAs can be used as early detectable peripheral biomarkers AD, as reported…”
Significance of GABAA Receptor for Cognitive Function and Hippocampal Pathology
Sakimoto, Y., Oo, P. M.-T., Goshima, M., Kanehisa, I., Tsukada, Y., & Mitsushima, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212456 · Cited by 86
Pyrazoline Containing Compounds as Therapeutic Targets for Neurodegenerative Disorders
Ahsan, M. J., Ali, A., Ali, A., Thiriveedhi, A., Bakht, M. A., Yusuf, M., Salahuddin, S., Afzal, O., & Altamimi, A. S. A. (2022) · ACS Omega · doi:10.1021/acsomega.2c05339 · Cited by 83
Qiao, Y., Chi, Y., Zhang, Q., & Ma, Y. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1169499 · Cited by 91
“For instance, aducanumab has been demonstrated to delay the clinical progression of AD, which has selectivity for fibrillary amyloid results in support of the amyloid hypothesis (Sevigny et al., 2016).”
Anti-amyloid-β protein agents for the treatment of Alzheimer’s disease: an update on emerging drugs
Lozupone, M., Solfrizzi, V., D’Urso, F., Di Gioia, I., Sardone, R., Dibello, V., Stallone, R., Liguori, A., Ciritella, C., Daniele, A., et al. (2020) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2020.1808621 · Cited by 77
Röhr, D., Boon, B. D. C., Schuler, M., Kremer, K., Hoozemans, J. J. M., Bouwman, F. H., El-Mashtoly, S. F., Nabers, A., Großerueschkamp, F., Rozemuller, A. J. M., et al. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-01091-5 · Cited by 77
“The discussion is fueled by several failed clinical studies of Aβ-targeting antibodies, as well as encouraging results of most recent anti-Aβ drug studies [77, 12, 67].”
ResultPharmacotherapy of Alzheimer’s Disease: Seeking Clarity in a Time of Uncertainty
Husna Ibrahim, N., Yahaya, M. F., Mohamed, W., Teoh, S. L., Hui, C. K., & Kumar, J. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00261 · Cited by 72
“(Ostrowitzki et al., 2017) Aducanumab IgG1 humanized antiAb mAbs III Mild-tomoderate AD Lack of efficacy (Selkoe, 2019) (Haeberlein et al., 2018) (Sevigny et al., 2016) Tramiprosate Ab aggregation inhibitor II Lack of efficacy (Selkoe, 2011) (Sabbagh, 2017) (Kocis et al., 2017) (Malouf and Collins,…”
BackgroundHaddad, H. W., W. Malone, G., J. Comardelle, N., E. Degueure, A., M. Kaye, A., & D. Kaye, A. (2022) · Health Psychology Research · doi:10.52965/001c.31925 · Cited by 71
Modified titration of donanemab reduces ARIA risk and maintains amyloid reduction
Wang, H., Nery, E. S. M., Ardayfio, P. A., Khanna, R., Svaldi, D. O., Gueorguieva, I., Shcherbinin, S., Andersen, S. W., Hauck, P. M., Engle, S. E., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70062 · Cited by 89
Self-citationAdvances in metal ion–mediated macromolecular drug delivery
Li, K., Yang, J., Peng, Y., Zheng, H., Fu, Z.-Z., Li, M., Zhou, W., & Yu, G. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.126501 · Cited by 111
Self-citationJian, C., Lu, M., Zhang, Z., Liu, L., Li, X., Huang, F., Xu, N., Qin, L., Zhang, Q., & Zou, D. (2017) · Life Sciences · doi:10.1016/j.lfs.2017.05.023 · Cited by 80
Detecting At-Risk Alzheimer’s Disease Cases
Fladby, T., Pålhaugen, L., Selnes, P., Waterloo, K., Bråthen, G., Hessen, E., Almdahl, I. S., Arntzen, K.-A., Auning, E., Eliassen, C. F., et al. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-170231 · Cited by 74
Pre-critical fluctuations and what they disclose about heterogeneous crystal nucleation
Fitzner, M., Sosso, G. C., Pietrucci, F., Pipolo, S., & Michaelides, A. (2017) · Nature Communications · doi:10.1038/s41467-017-02300-x · Cited by 81
“(3)), which is incompatible with the differences in precritical cluster sizes we observe.”
Bergen, J. M. G. V., Li, X., Quevenco, F. C., Gietl, A. F., Treyer, V., Meyer, R., Buck, A., Kaufmann, P. A., Nitsch, R. M., van Zijl, P. C. M., et al. (2018) · NeuroImage · doi:10.1016/j.neuroimage.2018.03.021 · Cited by 81
Self-citationPreclinical validation of a potent γ-secretase modulator for Alzheimer’s disease prevention
Rynearson, K. D., Ponnusamy, M., Prikhodko, O., Xie, Y., Zhang, C., Nguyen, P., Hug, B., Sawa, M., Becker, A., Spencer, B., et al. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20202560 · Cited by 76
LaClair, K. D., Donde, A., Ling, J. P., Jeong, Y. H., Chhabra, R., Martin, L. J., & Wong, P. C. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1637-y · Cited by 89
Reactive Amphiphilic Conjugated Polymers for Inhibiting Amyloid β Assembly
Sun, H., Liu, J., Li, S., Zhou, L., Wang, J., Liu, L., Lv, F., Gu, Q., Hu, B., Ma, Y., et al. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201901459 · Cited by 76
Parodi-Rullán, R. M., Javadov, S., & Fossati, S. (2021) · Cells · doi:10.3390/cells10112903 · Cited by 73
“In 2021, after nearly twenty years of attempts to develop new therapeutic strategies, aducanumab, a human monoclonal antibody that selectively targets aggregated amyloid-β (Aβ), has been approved by the FDA (through the accelerated approval pathway) for treatment of patients with AD [2].”
BackgroundCurrent views on meningeal lymphatics and immunity in aging and Alzheimer’s disease
Rego, S., Sánchez, G., & Mesquita, S. D. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00645-0 · Cited by 82
“…anti-Aβ passive immunotherapy in thwarting cognitive decline, concerns about the development of side effects (e.g., brain micro-bleeds and amyloid-related imaging abnormalities) that might compromise the final therapeutic outcome, and apprehension about the high cost of such treatments [200–202].”
BackgroundFruhwürth, S., Zetterberg, H., & Paludan, S. R. (2024) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2024.578342 · Cited by 74
“During anti-A β immunotherapies, microglia are believed to take part in A β clearance via Fc γ R-mediated phagocytosis of antibody-A β complexes (Bard et al., 2000; Demattos et al., 2012; Ostrowitzki et al., 2012; Sevigny et al., 2016).”
Molecular Insights into Human Serum Albumin as a Receptor of Amyloid-β in the Extracellular Region
Choi, T. S., Lee, H. J., Han, J. Y., Lim, M. H., & Kim, H. I. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.7b08584 · Cited by 80
Cao, Q., Shin, W. S., Chan, H., Vuong, C. K., Dubois, B., Li, B., Murray, K. A., Sawaya, M. R., Feigon, J., Black, D. L., et al. (2018) · Nature Chemistry · doi:10.1038/s41557-018-0147-z · Cited by 75
Phase II clinical trials of anti–amyloid β antibodies: When is enough, enough?
Gold, M. (2017) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.04.005 · Cited by 75
“[50] Sevigny J, Chiao P, Bussiere T, Weinreb PH, Williams L,”
BackgroundCatalytic photooxygenation degrades brain Aβ in vivo
Nagashima, N., Ozawa, S., Furuta, M., Oi, M., Hori, Y., Tomita, T., Sohma, Y., & Kanai, M. (2021) · Science Advances · doi:10.1126/sciadv.abc9750 · Cited by 79
Metadata
- Authors
- Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., O’Gorman, J., Qian, F., Arastu, M., Li, M., Chollate, S., Brennan, M. S., Quintero-Monzon, O., Scannevin, R. H., Arnold, H. M., Engber, T., Rhodes, K., Ferrero, J., Hang, Y., Mikulskis, A., Grimm, J., Hock, C., Nitsch, R. M., & Sandrock, A.
- Affiliations
- Biogen (United States) (US)
- Light Chain Bioscience (Switzerland) (CH)
- Butler Hospital (US)
- University of Zurich (CH)
- Corresponding author
- Sandrock, Alfred
- ORCID
- Venue
- Nature
- Published
- 2016-08-31
- Volume
- 537
- Issue
- 7618
- Pages
- 50-56
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2510806376
- Cited by
- 3,059
- References
- 42
- Citations by year
- 2026: 186 · 2025: 340 · 2024: 389 · 2023: 332 · 2022: 416 · 2021: 326 · 2020: 263 · 2019: 231 · 2018: 268 · 2017: 252 · 2016: 52
- FWCI
- 214.30
- Type
- journal article
- Language
- en
- Update notices
- addendum (2017-06-22)
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Funders
- Biogen
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- aducanumab, Alzheimer's disease, amyloid plaques, anti-amyloid monoclonal antibodies, immunotherapy, amyloid hypothesis, transgenic mouse model, prodromal Alzheimer's disease, clinical deterioration, amyloid-related imaging abnormalities, drug safety and tolerability
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Amyloid, Animals, Brain, Disease Models, Animal, Dose-Response Relationship, Drug, Female, Humans, Male, Mice, Transgenic, Middle Aged, Models, Biological, Solubility, Amyloid beta-Peptides, Clinical Trials, Phase III as Topic, Mice, Plaque, Amyloid, Antibodies, Monoclonal, Humanized, Protein Aggregation, Pathological
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.